Last updated: July 26, 2026
Antivert is the brand of meclizine hydrochloride, an oral first-generation antihistamine used for vertigo and motion-sickness symptoms. Current patent and regulatory positioning is dominated by older, likely-expired small-molecule IP plus ongoing life-cycle protection (if any) for specific formulations. Clinical-trial activity for meclizine is limited relative to newer vertigo programs, so near-term market growth is driven by generic availability, guideline use, and periodic label or formulation changes rather than by new pivotal development programs.
What clinical trials are currently evaluating ANTIVERT (meclizine)?
No current, widely registered late-stage interventional trials for meclizine brand ANTIVERT with a clear primary endpoint set and sponsor for NDA-level development are visible from the standard public clinical-trial registries typically used for cross-company market triangulation.
What phase trials exist for meclizine in vertigo or motion sickness?
Across public registries, meclizine research is more frequently seen as:
- comparative or small mechanistic studies in motion sickness and dizziness,
- older trials used to support historical safety and effectiveness rather than new product approvals,
- studies in special populations (eg, vestibular disorders) that do not necessarily involve brand ANTIVERT.
What endpoints are usually assessed for meclizine trials?
Common endpoints in meclizine studies include:
- reduction in dizziness/vertigo symptom scores,
- motion sickness provocation outcomes,
- patient-reported nausea/vomiting frequency,
- time-to-relief and tolerability (sedation, psychomotor impairment).
What drug-comparator dynamics show up in meclizine research?
Where head-to-head designs exist, they most often compare meclizine with:
- other first-generation antihistamines (promethazine, dimenhydrinate),
- vestibular suppressants (where applicable),
- non-drug supportive interventions.
What is ANTIVERT’s regulatory status and Orange Book standing?
Antivert (meclizine hydrochloride) is an established drug with generic equivalents. Product-level exclusivity has historically expired; market access is therefore primarily generic-driven. The Orange Book status for meclizine products typically shows multiple ANDA approvals with expired listed patents or limited remaining formulation-specific protection depending on the specific strength, dosage form, and applicant.
What does this mean for future exclusivity windows?
- Meclizine’s core API and typical solid oral doses are not expected to have active long-term exclusivity blocks.
- Any remaining barriers are usually tied to formulation, manufacturing method, or narrow-use claims if present.
How does FDA labeling affect clinical use?
Label indications for dizziness and vertigo-related symptom control and motion sickness guidance drive demand. Label language changes, safety communications (sedation and impairment warnings), and OTC/Rx placement also shape uptake.
How many patents protect meclizine/ANTIVERT, and what kinds of patents exist?
No active, dominant patent estate for brand-level exclusivity is typical for meclizine because the underlying drug is old and widely generic. Patent coverage, where it exists, tends to be:
- old process or salt-related filings that have expired,
- formulation and packaging claims (less common at scale),
- method-of-use claims that may or may not be asserted in practice.
Which patent categories most affect market entry risk?
For an established small molecule like meclizine, generic entry risk usually comes from:
- formulation-specific patents (if any remain listed for a specific dosage form and applicant),
- method-of-use claims if tightly linked to label-supported dosing,
- REMS-related manufacturing constraints (unlikely for this drug class unless a current safety program exists).
When does ANTIVERT lose exclusivity, and what generic entry risks exist?
Given meclizine’s age and broad generic presence, exclusivity is effectively not a near-term gating factor. Market entry risk is mostly commercial (distribution, pricing) rather than legal (paragraphed patent life-cycle cliffs).
What would trigger a new exclusivity clock?
A new exclusivity event would require one of the following:
- a meaningful label expansion with qualifying clinical evidence,
- an identified new formulation qualifying for a separate exclusivity pathway,
- a new active moiety (not the case for meclizine).
What is the market size for meclizine/ANTIVERT and how is it trending?
ANTIVERT is a small-molecule vertigo/motion-sickness symptomatic therapy in a large OTC and generic-weighted market. Demand is supported by:
- chronic or episodic vestibular symptom management needs,
- motion sickness use-cases,
- broad physician and consumer familiarity.
Key market structure factors
- Generic substitution is the default consumer and pharmacy behavior.
- Pricing is compressed by multiple ANDA entrants.
- Product differentiation is mainly packaging, dosing convenience, and distribution channels.
Share-driving dynamics
Market share is influenced by:
- formulary placement (health systems, managed care),
- OTC availability and shelf positioning,
- payer coverage and copayment design.
Who competes with ANTIVERT, and how does each competitor’s product strategy compare?
ANTIVERT competes with:
- multiple meclizine generics in identical dosage strengths and regimens,
- other vertigo symptom suppressants (competing classes: antihistamines, anticholinergics, vestibular suppressants),
- non-drug interventions in some vestibular disorders.
Competitive comparison: brand vs generic
- Brand products typically command higher unit price but are constrained by therapeutic substitutability.
- Generics win volume through price and pharmacy stocking.
What market projection applies to ANTIVERT through 2030?
Projection: low-to-moderate value growth, flat-to-declining volume growth, and continued price pressure is the baseline profile for an established antihistamine with extensive generic penetration.
Base-case drivers
- steady symptomatic demand in vertigo and motion sickness,
- modest growth from population aging and persistent vestibular diagnosis rates,
- incremental growth from channel expansion (OTC and mail order).
Constraints
- continued generic price erosion,
- competitive displacement by alternative symptom-control agents where formularies dictate,
- limited incentive for large sponsors to run new registrational trials.
Value vs volume outlook
- Volume: likely stable with substitution across generics, with modest growth from aging demographics.
- Value: likely grows slower than volume due to pricing compression and wholesale discounting.
How do clinical and safety signals affect demand for meclizine?
Meclizine demand is sensitive to safety perception and labeling emphasis on:
- sedation and impairment risk,
- cognitive effects,
- contraindications in specific populations.
Safety communications can reduce use in certain segments, while stable safety experience supports ongoing OTC and Rx demand.
Where do the main development opportunities sit if new trials restart for meclizine?
Any renewed clinical activity for meclizine would most likely target:
- vestibular symptom subtypes (eg, disorder-specific cohorts) with symptom scoring,
- comparative effectiveness against other vestibular suppressants in real-world designs,
- alternative dosing regimens or improved tolerability formulations.
Key Takeaways
- ANTIVERT is meclizine hydrochloride, a mature, generic-dominated symptomatic vertigo and motion-sickness therapy.
- Clinical-trial activity for meclizine is generally limited in scope and is not typically driven by brand-level registrational programs.
- Exclusivity is not a near-term market entry barrier; legal risk is secondary to generic competition and pricing.
- Market outlook through 2030 is expected to show modest value growth with continued price pressure and stable-to-slightly growing volume.
FAQs
-
Is ANTIVERT considered a first-line treatment for vertigo in clinical practice?
It is commonly used for symptomatic relief where vestibular suppressive antihistamines are appropriate, but guideline-first strategies vary by vertigo subtype and etiology.
-
Can ANTIVERT be used for motion sickness alongside other antihistamines?
Use is typically constrained by additive sedation and overlapping pharmacology; clinicians generally avoid duplicative first-generation antihistamine therapy.
-
What adverse effects most limit ANTIVERT uptake?
Sedation and impaired psychomotor function are the dominant practical barriers, especially for daytime use.
-
Do new formulation patents meaningfully delay generic meclizine entry?
For meclizine, generic penetration has remained extensive; any formulation-specific barriers would need to be both active and product-specific to slow market access materially.
-
Is there potential for biosimilar-like competition with ANTIVERT?
No. Meclizine is a small molecule; the analogous pathway is generic and, where applicable, 505(b)(2) reformulation rather than biologics.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-26).
- U.S. FDA Label for Antivert (meclizine hydrochloride). (Accessed 2026-07-26).
- ClinicalTrials.gov. Search results for meclizine and vertigo/motion sickness indications. (Accessed 2026-07-26).
